The prolyl isomerase Pin1 regulates the NF-B signaling pathway and interleukin-8 expression in glioblastoma

Oncogene

Volumn 28, Issue 42, 2009, Pages 3735-3745

  Atkinson, G P ^a   Nozell, S E ^a   Harrison, D K ^b   Stonecypher, M S ^a   Chen, D ^c   Benveniste, E N ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NONE   (United States)

Author keywords

Gene expression; Glioblastoma; NF kB; Pin1; Signal transduction

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PEPTIDYLPROLYL ISOMERASE PIN1; SERINE; SHORT HAIRPIN RNA; SYNAPTOTAGMIN I; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; INTERLEUKIN-8; INVERTED REPEAT SEQUENCES; MICE; NF-KAPPA B; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRACYCLINE; TRANSCRIPTION FACTOR RELA;

EID: 70350567644     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.232     Document Type: Article

References (55)

1. Aggarwal BB. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208.
2. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J et al. (2003). The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 63: 6244-6251.
3. Baker BJ, Qin H, Benveniste EN. (2008). Molecular basis of oncostatin M-induced SOCS-3 expression in astrocytes. Glia 56: 1250-1262.
4. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, Wang DG. (2004). Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 164: 1727-1737.
5. Bharti AC, Aggarwal BB. (2002). Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883-888.
6. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. (2008). Glioblastoma in adults. Crit Rev Oncol Hematol 67: 139-152.
7. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K et al. (2008). Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14: 4694-4704.
8. Brat DJ, Bellail AC, Van Meir EG. (2005). The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol 7: 122-133.
9. Chandana SR, Movva S, Arora M, Singh T. (2008). Primary brain tumors in adults. Am Fam Physician 77: 1423-1430.
10. Choi C, Kutsch O, Park J, Zhou T, Seol DW, Benveniste EN. (2002). Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol 22: 724-736.
11. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN. (2006). The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci USA 103: 18715-18720.
12. Finn G, Lu KP. (2008). Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 8: 223-229.
13. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E et al. (2004). The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332.
14. Ghosh S, Karin M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109: S81-S96.
15. Gilmore T. (2008). Boston: MA. www.NF-kB.org, http://people.bu. edu/gilmore/nf-kb/index.html.
16. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296.
17. Harant H, de Martin R, Andrew PJ, Foglar E, Dittrich C, Lindley IJ. (1996). Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB. J Biol Chem 271: 26954-26961.
18. Hayden MS, Ghosh S. (2004). Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
19. Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell 132: 344-362.
20. Hoffmann A, Leung TH, Baltimore D. (2003). Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J 22: 5530-5539.
21. Hoffmann A, Levchenko A, Scott ML, Baltimore D. (2002a). The I-kappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298: 1241-1245.
22. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. (2002b). Multiple control of interleukin-8 gene expression. J Leukoc Biol 72: 847-855.
23. Jang HD, Yoon K, Shin YJ, Kim J, Lee SY. (2004). PIAS3 suppresses NF-\{kappa\}B-mediated transcrip. J Biol Chem 279: 24873-24880.
24. Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
25. Karin M, Cao Y, Greten FR, Li ZW. (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310.
26. Karin M, Lin A. (2002). NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
27. Li S, Wang L, Berman MA, Zhang Y, Dorf ME. (2006). RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell 24: 497-509.
28. Lu KP. (2003). Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell 4: 175-180.
29. Lu KP, Zhou XZ. (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8: 904-916.
30. Lufei C, Koh TH, Uchida T, Cao X. (2007). Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 26: 7656-7664.
31. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. (2002). Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96: 909-917.
32. Nozell S, Laver T, Moseley D, Nowoslawski L, Devos M, Atkinson GP et al. (2008). The ING4 tumor suppressor attenuates NF-\{kappa\}B activity at the promoter of target genes. Mol Cell Biol 28: 6632-6645.
33. Nozell S, Laver T, Patel K, Benveniste EN. (2006). Mechanism of IFN-beta-mediated inhibition of IL-8 gene expression in astro-glioma cells. J Immunol 177: 822-830.
34. Nozell S, Ma Z, Wilson C, Shah R, Benveniste EN. (2004). Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J Biol Chem 279: 38577-38589.
35. Pang R, Lee T, Man K, Poon R, Fan ST, Kwong YL et al. (2006). PIN1 expression contributes to hepatic carcinogenesis. J Pathol 210: 19-25.
36. Perkins ND. (2006). Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25: 6717-6730.
37. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. (2007). Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 85: 39-47.
38. Ryo A, Hirai A, Nishi M, Liou YC, Perrem K, Lin SC et al. (2007). A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx. J Biol Chem 282: 36671-36681.
39. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP. (2002). PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22: 5281-5295.
40. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G et al. (2003). Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12: 1413-1426.
41. Ryo A, Uemura H, Ishiguro H, Saitoh T, Yamaguchi A, Perrem K et al. (2005). Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 11: 7523-7531.
42. Saccani S, Pantano S, Natoli G. (2001). Two waves of nuclear factor kappaB recruitment to target promoters. J Exp Med 193: 1351-1359.
43. Smith D, Shimamura T, Barbera S, Bejcek BE. (2007). NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 307: 141-147.
44. Stewart LA. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
45. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. (2006). Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42: 768-778.
46. Stupp R, Dietrich P-Y, Kraljevic SO, Pica A, Maillard I, Maeder P et al. (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Onc 20: 1375-1382.
47. Vila-Carriles WH, Kovacs GG, Jovov B, Zhou ZH, Pahwa AK, Colby G et al. (2006). Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. J Biol Chem 281: 19220-19232.
48. Wakabayashi K, Kambe F, Cao X, Murakami R, Mitsuyama H, Nagaya T et al. (2004). Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells. Oncogene 23: 6924-6932.
49. Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. (2004). Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951.
50. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V et al. (2001). Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20: 3459-3472.
51. Xu YX, Manley JL. (2007). Pin1 modulates RNA polymerase II activity during the transcription cycle. Genes Dev 21: 2950-2962.
52. Yamamoto M, Fukushima T, Hayashi S, Ikeda K, Tsugu H, Kimura H et al. (2000). Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 20: 611-618.
53. Yeh ES, Means AR. (2007). PIN1, the cell cycle and cancer. Nat Rev Cancer 7: 381-388.
54. Zhong H, May MJ, Jimi E, Ghosh S. (2002). The phosphorylation status of nuclear NF-kappa B determines its association with CBP/ p300 or HDAC-1. Mol Cell 9: 625-636.
55. Zhong H, Voll RE, Ghosh S. (1998). Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1: 661-671.